Your browser doesn't support javascript.
loading
Urea cycle disorders-update.
Matsumoto, Shirou; Häberle, Johannes; Kido, Jun; Mitsubuchi, Hiroshi; Endo, Fumio; Nakamura, Kimitoshi.
Afiliación
  • Matsumoto S; Department of Pediatrics, Graduate School of Medical Sciences, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan. s-pediat@gpo.kumamoto-u.ac.jp.
  • Häberle J; University Children's Hospital Zurich and Children's Research Centre, Zurich, 8032, Switzerland.
  • Kido J; Department of Pediatrics, Graduate School of Medical Sciences, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
  • Mitsubuchi H; Department of Pediatrics, Graduate School of Medical Sciences, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
  • Endo F; Kumamoto Ezuko Institution for Developmental Disabilities, Kumamoto, Japan.
  • Nakamura K; Department of Pediatrics, Graduate School of Medical Sciences, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
J Hum Genet ; 64(9): 833-847, 2019 Sep.
Article en En | MEDLINE | ID: mdl-31110235
ABSTRACT
The urea cycle is a metabolic pathway for the disposal of excess nitrogen, which arises primarily as ammonia. Nitrogen is essential for growth and life-maintenance, but excessive ammonia leads to life-threatening conditions. The urea cycle disorders (UCDs) comprise diseases presenting with hyperammonemia that arise in either the neonatal period (about 50% of cases) or later. Congenital defects of the enzymes or transporters of the urea cycle cause the disease. This cycle utilizes five enzymes, two of which, carbamoylphosphate synthetase 1 and ornithine transcarbamylase are present in the mitochondrial matrix, whereas the others (argininosuccinate synthetase, argininosuccinate lyase and arginase 1) are present in the cytoplasm. In addition, N-acetylglutamate synthase and at least two transporter proteins are essential to urea cycle function. Severity and age of onset depend on residual enzyme or transporter function and are related to the respective gene mutations. The strategy for therapy is to prevent the irreversible toxicity of high-ammonia exposure to the brain. The pathogenesis and natural course are poorly understood because of the rarity of the disease, so an international registry system and novel clinical trials are much needed. We review here the current concepts of the pathogenesis, diagnostics, including genetics and treatment of UCDs.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Ornitina Carbamoiltransferasa / Arginasa / Encéfalo / Carbamoil-Fosfato Sintasa (Amoniaco) / Trastornos Innatos del Ciclo de la Urea / Mutación Límite: Humans Idioma: En Revista: J Hum Genet Asunto de la revista: GENETICA MEDICA Año: 2019 Tipo del documento: Article País de afiliación: Japón

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Ornitina Carbamoiltransferasa / Arginasa / Encéfalo / Carbamoil-Fosfato Sintasa (Amoniaco) / Trastornos Innatos del Ciclo de la Urea / Mutación Límite: Humans Idioma: En Revista: J Hum Genet Asunto de la revista: GENETICA MEDICA Año: 2019 Tipo del documento: Article País de afiliación: Japón